开发用于中风血栓溶解的基酶:日本的努力
1Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan. toyoda@ncvc.go.jp.
概括
丁氏甲在急性缺血性中风治疗方面表现有前途,为阿尔特氏甲提供了替代品. 这项在日本进行的研究比较了甲与低剂量高甲,重点关注大血管封闭性中风患者的早期再输液.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 静脉内血栓溶解对于急性缺血性中风至关重要,但阿尔泰的疗效有限.
- 内出血是一个重要的风险,特别是在高血压的亚洲人群中.
- 丁氏甲正在成为推的血栓解压剂,监管部门的批准在全球范围内扩大.
研究的目的:
- 在日本急性缺血性中风患者中,比较基的疗效与低剂量基的疗效.
- 评估成功的早期再输血作为大型血管封闭符合机械血栓切除的患者的主要结局.
主要方法:
- 进行了一项由研究者发起的,多中心的,前性的,随机的,开放的,掩盖的终点,优越性试验 (T-FLAVOR).
- 这项试验比较了在发病后4.5小时内发生大血管封闭性中风的患者中用低剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量的低剂量高剂量高剂量高剂量的低剂量高剂量高剂量高剂量高剂量高剂量的低剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高剂量高.
- 参与者还有资格在发病6小时内接受机械血栓切除术.
主要成果:
- 220名参与者的注册已经完成,预计2025年将获得结果.
- 这项试验是日本唯一的一项甲酸研究,也是全球首个直接比较甲酸与低剂量高甲酸 (0.6 mg/kg) 的试验.
结论:
- 这项T-FLAVOR试验将提供关于日本人口中基的疗效和安全性的关键数据.
- 预计这些发现将为日本和潜在的其他亚洲国家提供治疗指南和对tenecteplase的监管决定的信息.
相关概念视频
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:15Ischemic Stroke l: Introduction
Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.
01:15Ischemic Stroke ll: Pathophysiology
An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
01:17Hemorrhagic Stroke l: Introduction
A hemorrhagic stroke is an acute neurological event that occurs when a weakened cerebral blood vessel ruptures, allowing blood to accumulate within or around the brain. The sudden release of blood forms a focal hematoma that increases intracranial pressure, displaces neural tissue, and can obstruct cerebrospinal fluid pathways. These effects may be compounded by intraventricular extension of the hemorrhage, cerebral edema, or compression of adjacent structures, all of which contribute to...
01:29Hemorrhagic Stroke ll: Pathophysiology
A hemorrhagic stroke develops when a cerebral blood vessel ruptures, allowing blood to escape into the surrounding brain tissue, as in intracerebral hemorrhage (ICH), or into the subarachnoid space, as in subarachnoid hemorrhage (SAH). Because the skull is a rigid compartment, the sudden presence of extravascular blood rapidly increases intracranial pressure and compresses adjacent neural structures, leading to immediate tissue injury and impaired cerebral perfusion.Mass Effect and Primary...
01:26Transient Ischemic Attack l: Introduction
A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...